The prestigious international journal, “Frontiers in Immunology”, has recently published a paper about the Immunobiogram technology, called “The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy” . Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. With an Impact Factor of 6.429, Frontiers in Immunology is the 5th most cited Immunology journal in the world.
Key findings in the paper are:
- Not all patients respond equally to a given immunosuppressant drug. This is due to individual differences in pharmacokinetic and pharmacodynamic responses to drugs
- The IMBG test allows quantification of each patient’s sensitivity to their prescribed immunosuppressant medication. Furthermore, we observed an association between patient treatment results and the immunological risk of rejection of the corresponding patient
- Patients with a greater risk of rejection showed reduced sensitivity to their prescribed immunosuppressant, while those with the lowest risk of rejection showed greater sensitivity to their prescribed medication.
- The IMBG assay thus provides pharmacodynamic information linked to the final efficacy of the patient’s prescribed immunosuppressant(s), which influences their risk of rejection
Please click this link to have full access to the paper.